155 related articles for article (PubMed ID: 11807301)
1. Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients.
d'Ettorre G; Forcina G; Lichtner M; Mengoni F; D'Agostino C; Massetti AP; Mastroianni CM; Vullo V
AIDS; 2002 Jan; 16(2):181-8. PubMed ID: 11807301
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy.
Forcina G; D'Ettorre G; Mastroianni CM; Carnevalini M; Scorzolini L; Ceccarelli G; D'Agostino C; Lichtner M; Massetti AP; Vullo V
Cytokine; 2004 Mar; 25(6):283-90. PubMed ID: 15036244
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy.
d'Ettorre G; Forcina G; Andreotti M; Sarmati L; Palmisano L; Andreoni M; Vella S; Mastroianni CM; Vullo V
Clin Exp Immunol; 2004 Feb; 135(2):280-5. PubMed ID: 14738457
[TBL] [Abstract][Full Text] [Related]
4. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia. The Master Group.
Clerici M; Seminari E; Suter F; Castelli F; Pan A; Biasin M; Colombo F; Trabattoni D; Maggiolo F; Carosi G; Maserati R
AIDS; 2000 Jan; 14(2):109-16. PubMed ID: 10708280
[TBL] [Abstract][Full Text] [Related]
5. Recovery of interleukin-17 production from interleukin-15-stimulated CD4+ mononuclear cells in HIV-1-infected patients with sustained viral suppression.
Zaffiri L; d'Ettorre G; Ceccarelli G; Andreotti M; Marcellini S; Giustini N; Ascoli-Bartoli T; Mastroianni CM; Vella S; Vullo V
J Interferon Cytokine Res; 2014 Jan; 34(1):35-40. PubMed ID: 24102576
[TBL] [Abstract][Full Text] [Related]
6. Circulating levels of interleukin-7 in antiretroviral-naïve and highly active antiretroviral therapy-treated HIV-infected patients.
Mastroianni CM; Forcina G; d'Ettorre G; Lichtner M; Mengoni F; D'Agostino C; Vullo V
HIV Clin Trials; 2001; 2(2):108-12. PubMed ID: 11590518
[TBL] [Abstract][Full Text] [Related]
7. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection.
Montes de Oca Arjona M; Pérez Cano R; Orozco MJ; Martín Aspas A; Guerrero F; Fernández Gutiérrez Del Alamo C; Girón-González JA
Clin Microbiol Infect; 2005 Jan; 11(1):57-62. PubMed ID: 15649305
[TBL] [Abstract][Full Text] [Related]
8. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
[TBL] [Abstract][Full Text] [Related]
9. An IL-15 dependent CD8 T cell response to selected HIV epitopes is related to viral control in early-treated HIV-infected subjects.
D'Offizi G; Gioia C; Corpolongo A; Martini F; Paganelli R; Volpi I; Sacchi A; Tozzi V; Narciso P; Poccia F
Int J Immunopathol Pharmacol; 2007; 20(3):473-85. PubMed ID: 17880761
[TBL] [Abstract][Full Text] [Related]
10. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1.
Vicenzi E; Alfano M; Ghezzi S; Gatti A; Veglia F; Lazzarin A; Sozzani S; Mantovani A; Poli G
J Leukoc Biol; 2000 Sep; 68(3):405-12. PubMed ID: 10985258
[TBL] [Abstract][Full Text] [Related]
11. Immune activation and IL-12 production during acute/early HIV infection in the absence and presence of highly active, antiretroviral therapy.
Byrnes AA; Harris DM; Atabani SF; Sabundayo BP; Langan SJ; Margolick JB; Karp CL
J Leukoc Biol; 2008 Dec; 84(6):1447-53. PubMed ID: 18806124
[TBL] [Abstract][Full Text] [Related]
12. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
13. Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients.
Stylianou E; Bjerkeli V; Yndestad A; Heggelund L; Waehre T; Damås JK; Aukrust P; Frøland SS
Clin Exp Immunol; 2003 Jun; 132(3):462-6. PubMed ID: 12780693
[TBL] [Abstract][Full Text] [Related]
14. Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production.
D'Ettorre G; Forcina G; Andreotti M; Sarmati L; Palmisano L; Galluzzo CM; Nicastri E; Mastroianni CM; Vullo V; Vella S; Andreoni M
AIDS; 2002 Sep; 16(14):1877-85. PubMed ID: 12351947
[TBL] [Abstract][Full Text] [Related]
15. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
Bart PA; Rizzardi GP; Tambussi G; Chave JP; Chapuis AG; Graziosi C; Corpataux JM; Halkic N; Meuwly JY; Munoz M; Meylan P; Spreen W; McDade H; Yerly S; Perrin L; Lazzarin A; Pantaleo G
AIDS; 2000 Sep; 14(13):1887-97. PubMed ID: 10997391
[TBL] [Abstract][Full Text] [Related]
16. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
[TBL] [Abstract][Full Text] [Related]
17. Highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responses.
Blazevic V; Jankelevich S; Steinberg SM; Jacobsen F; Yarchoan R; Shearer GM
Clin Diagn Lab Immunol; 2001 Sep; 8(5):943-8. PubMed ID: 11527808
[TBL] [Abstract][Full Text] [Related]
18. Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients.
Clerici M; Seminari E; Maggiolo F; Pan A; Migliorino M; Trabattoni D; Castelli F; Suter F; Fusi ML; Minoli L; Carosi G; Maserati R;
AIDS; 2002 Sep; 16(13):1767-73. PubMed ID: 12218388
[TBL] [Abstract][Full Text] [Related]
19. Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.
Bukh AR; Melchjorsen J; Offersen R; Jensen JM; Toft L; Støvring H; Ostergaard L; Tolstrup M; Søgaard OS
PLoS One; 2011; 6(6):e21275. PubMed ID: 21731690
[TBL] [Abstract][Full Text] [Related]
20. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2.
Zanussi S; Simonelli C; Bortolin MT; D'Andrea M; Crepaldi C; Vaccher E; Nasti G; Politi D; Barzan L; Tirelli U; De Paoli P
Clin Exp Immunol; 1999 Jun; 116(3):486-92. PubMed ID: 10361239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
